Evidence map›Paper›PMID 31823081›Full record

ArticleJournal of medical systems2019

Can we Predict Preoperative Tumor Aggressivity with Hemogram Parameters in Renal Cell Carcinoma? a Novel Calculation Method.

Murat Uçar, Sedat Soyupek, Taylan Oksay, Alper Özorak, Ali Akkoç, Murat Topçuoğlu, Murat Demir, Alim Koşar

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of medical systems, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Murat UçarAlanya Alaaddin Keykubat University, School of Medicine, Antalya, Turkey. murat.ucar@alanya.edu.tr.ORCID http://orcid.org/0000-0002-8690-0485
Sedat SoyupekSüleyman Demirel University, School of Medicine, Isparta, Turkey.
Taylan OksaySüleyman Demirel University, School of Medicine, Isparta, Turkey.
Alper ÖzorakSüleyman Demirel University, School of Medicine, Isparta, Turkey.
Ali AkkoçAlanya Alaaddin Keykubat University, School of Medicine, Antalya, Turkey.
Murat TopçuoğluAlanya Alaaddin Keykubat University, School of Medicine, Antalya, Turkey.
Murat DemirSüleyman Demirel University, School of Medicine, Isparta, Turkey.
Alim KoşarSüleyman Demirel University, School of Medicine, Isparta, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aim to investigate the prognostic significance of the hemoglobin X lymphocyte / neutrophil ratio (HLNR) and hemoglobin x lymphocyte / platelet ratio (HLPR) with tumor aggressivity in patients with renal cell carcinoma. We retrospectively analyzed 127 patients' data who had diagnosed as renal cell carcinoma between 2008 and 2019 in Suleyman Demirel University Hospital. Tumor and patient characteristics, hemoglobin, neutrophil, lymphocyte, platelet values HLNR and HLPR were calculated in preoperative hemogram parameters. The relationship between tumor pathological stage, Fuhrman nuclear grade and tumor necrosis with HLPR and HLNR analyzed with statistically. There was a negative correlation between pathologic stage, Fuhrman nuclear grade and tumor necrosis with HLNR. P values are 0.003, 0.012 and 0.015 respectively. HLNR was lower in patients with high pathologic stage, high Fuhrman nuclear grade and accompanying tumor necrosis positiveness. There was a negative correlation between pathologic stage, Fuhrman nuclear grade and tumor necrosis with HLPR. P values are 0.001, 0.014 and 0.047 respectively. HLPR was lower in patients with high pathologic stage, high Fuhrman nuclear grade and accompanying tumor necrosis positiveness. High pathological stage, high Fuhrman nuclear grade and existence of tumor necrosis are associates with preoperative low HLNR and low HLPR in renal cell carcinoma patients. They can be used as prognostic markers in patients with renal mass preoperatively.

Indexed as

VirulenceAdultAgedAged, 80 and overCarcinoma, Renal CellFemaleHematologic TestsHumansMaleMiddle AgedPrognosisRetrospective StudiesCarcinoma renal cellHematologic testsKidneyPrognosis

Identifiers

PMID31823081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.